Dynamics of serum antithyroglobulin antibodies in patients with differentiated thyroid cancer

Purpose Serum antithyroglobulin antibodies (sTgAb) affect the reliability of Tg measurement in patients with thyroid cancer. We compared the outcome of patients with detectable and undetectable sTgAb, stratified according to the initial risk of recurrence (RR); also the response to treatment in pati...

Full description

Saved in:
Bibliographic Details
Published in:Endocrine 2020-02, Vol.67 (2), p.387-396
Main Authors: Bueno, Fernanda, Falcone, María Gabriela García, Peñaloza, Mirna Angela, Abelleira, Erika, Pitoia, Fabián
Format: Article
Language:English
Subjects:
Antibodies
Diabetes
Endocrinology
Humanities and Social Sciences
Internal Medicine
Medicine
Medicine & Public Health
multidisciplinary
Original Article
Patients
Science
Statistical analysis
Thyroid cancer
Thyroidectomy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Serum antithyroglobulin antibodies (sTgAb) affect the reliability of Tg measurement in patients with thyroid cancer. We compared the outcome of patients with detectable and undetectable sTgAb, stratified according to the initial risk of recurrence (RR); also the response to treatment in patients with detectable sTgAb treated with total thyroidectomy (TT) with and without radioiodine remnant ablation (RA) and the sTgAb trend in the long-term follow-up according to the initial response. Methods We included 432 patients submitted to TT, with or without RA; 106 patients had detectable sTgAb levels. Median follow-up was 53 months. Results There were no statistically significant differences considering presentation between negative or positive sTgAb subjects. The frequency of structural incomplete response (SIR) in low, intermediate, and high RR was similar. Undetectable sTgAb in patients was achieved in a median of 16 months in ablated patients compared with 11 months in those without RA ( p  = 0.0232). Patients without RA had a higher rate of undetectable sTgAb during the first 12 months. A SIR was observed in 3% of patients with declining sTgAb, in 19% of those with stable levels, and in 43% with increasing sTgAb ( p  = 0.004). The status of no evidence of disease was achieved more frequently in patients with initial sTgAb levels 
ISSN:1355-008X
1559-0100
DOI:10.1007/s12020-019-02112-7